Patisiran prevents functional decline in patients with cardiac amyloidosis

1. In this randomized controlled trial, patisiran demonstrated a reduction in functional capacity decline transthyretin amyloidosis (ATTR amyloidosis) with a cardiac component as compared to placebo. 2. Compared to placebo, patisiran demonstrated a higher rate of infusion-related reactions, arthralgias, and muscle spasms. Evidence Rating Level: 1 (Excellent) Study Rundown: ATTR amyloidosis is a serious condition

Related Keywords

,Minute Medicine Inc ,Rating Level ,Kansas City Cardiomyopathy Questionnaire ,Overall Summary ,Amyloid Fibrils ,Attr Amyloidosis ,Cardiac Amyloidosis ,Cardiology ,Chronic Disease ,Patisiran ,Transthyretin Amyloidosis ,Transthyretin Amyloidosis Attr ,